Project Grant W81XWH1510702

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $444,125 in funding to Duke University to explore the role of the LRRC55 regulatory protein in pain pathways. The key objectives are to: 1) delineate LRRC55's function in chronic pain behaviors using genetically-modified mice, 2) quantify changes in LRRC55 expression in dorsal root ganglion and spinal cord neurons...

This Project Grant award of $2,068,842 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to identify how pain influences the activity of prefrontal cortical dynorphin neurons and their role in modulating nociception and maladaptive affective behaviors. The research aims to dissect the mechanisms by which dynorphin neurons and release of dynorphin neuropeptides or fast neurotransmitters...

The University of Miami is conducting a research project under a $1,109,446 Cooperative Agreement awarded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH). The project, funded through the Drug Abuse and Addiction Research Programs (CFDA 93.279), aims to develop a novel non-opioid analgesic based on gene therapy targeting the carbonic anhydrase-8 (CA8) protein to treat chronic pain associated with knee osteoarthritis. The...

This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...

This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...

This Project Grant award from the National Institutes of Health's John E. Fogarty International Center (CFDA 93.989 - International Research and Research Training) provides $5,000 to the University of California, San Diego to discover novel natural products that are potent blood-brain barrier (BBB) permeable inhibitors of the enzyme cathepsin L. The goal is to identify a lead drug candidate that can reduce spinal dynorphin and alleviate chronic pain without the risk of addiction, which is a...

This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $2,505,537 to The Leland Stanford Junior University to develop a focused ultrasound (FUS) device for noninvasive, peripheral nerve blockade to manage acute pain. The goal is to provide an alternative to opioids and current peripheral nerve block techniques, which have significant limitations in acute pain management. The...

This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) provides $376,310 to the University of North Carolina at Chapel Hill to develop the necessary documents and procedures to conduct a 16-week randomized controlled trial. The trial will test the efficacy and biochemical mechanisms of a dietary intervention involving increasing omega-3 fatty acids (EPA...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $399,870 to 2Morrow Inc. to accelerate the commercialization and dissemination of their evidence-based digital behavioral therapeutic for individuals with chronic pain. The funding will be used to hire a fractional Chief Commercial Officer (CCO) to review and validate 2Morrow's commercialization plan, and then execute a...